UroGen Pharma Appoints Former Kite Pharma Executive Christine Cassiano as Corporate Affairs Officer
January 08, 2018 08:00 ET
|
UroGen Pharma Ltd.
Kate Bechtold, Also Formerly of Kite Pharma, to Join the Expanded Communications Team as Director of Corporate Communications & Investor Relations RA’ANANA, Israel, and NEW YORK, Jan. 08, 2018 ...
UroGen Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 02, 2018 08:00 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Expands Clinical Development Leadership Team
December 12, 2017 08:30 ET
|
UroGen Pharma Ltd.
Mark Schoenberg, M.D., Named Chief Medical Officer Elyse Seltzer, M.D., Appointed Senior Vice President of Clinical Development RA'ANANA, Israel and NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) --...
UroGen Pharma Announces Oral Presentation at Society of Urologic Oncology (SUO) Annual Meeting
November 27, 2017 08:30 ET
|
UroGen Pharma Ltd.
Principal Investigator Seth Lerner, M.D., to present design overview of ongoing Phase 3 OLYMPUS trial of MitoGel™ for the treatment of Low-Grade UTUC and data highlights from recently completed...
UroGen Pharma Reports Third Quarter 2017 Financial Results and Recent Corporate Developments
November 14, 2017 07:00 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, Nov. 14, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma to Present at the Jefferies 2017 London Healthcare Conference
November 09, 2017 08:30 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma to Host Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017
November 08, 2017 08:30 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, Nov. 08, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Announces First Patient Enrolled in Allergan Phase 2 Clinical Trial of RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder
November 06, 2017 08:30 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, Nov. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Appoints Former Kite Pharma Chief Operating Officer Cynthia M. Butitta to its Board of Directors
November 02, 2017 08:30 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel and NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...
UroGen Pharma Expands Leadership Team, Appoints Industry Veterans Jeffrey Bova as Vice President of Commercial and James Ottinger as Vice President of Regulatory Affairs
October 26, 2017 08:30 ET
|
UroGen Pharma Ltd.
RA’ANANA, Israel, and NEW YORK, Oct. 26, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the...